+

WO2004113275A3 - Methods and compositions for treating amyloid-related diseases - Google Patents

Methods and compositions for treating amyloid-related diseases Download PDF

Info

Publication number
WO2004113275A3
WO2004113275A3 PCT/IB2004/002375 IB2004002375W WO2004113275A3 WO 2004113275 A3 WO2004113275 A3 WO 2004113275A3 IB 2004002375 W IB2004002375 W IB 2004002375W WO 2004113275 A3 WO2004113275 A3 WO 2004113275A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
related diseases
treating amyloid
treating
Prior art date
Application number
PCT/IB2004/002375
Other languages
French (fr)
Other versions
WO2004113275A2 (en
Inventor
Xianqi Kong
David Migneault
Isabelle Valade
Xinfu Wu
Francine Gervais
Original Assignee
Neurochem Int Ltd
Xianqi Kong
David Migneault
Isabelle Valade
Xinfu Wu
Francine Gervais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/871,514 external-priority patent/US7414076B2/en
Priority claimed from US10/871,365 external-priority patent/US7244764B2/en
Priority to KR1020057024647A priority Critical patent/KR101124935B1/en
Priority to NZ544684A priority patent/NZ544684A/en
Priority to AU2004249529A priority patent/AU2004249529A1/en
Priority to MXPA05014166A priority patent/MXPA05014166A/en
Priority to CA2529257A priority patent/CA2529257C/en
Priority to EP04744034A priority patent/EP1644325A2/en
Application filed by Neurochem Int Ltd, Xianqi Kong, David Migneault, Isabelle Valade, Xinfu Wu, Francine Gervais filed Critical Neurochem Int Ltd
Priority to BRPI0411743-3A priority patent/BRPI0411743A/en
Priority to JP2006516599A priority patent/JP5146714B2/en
Priority to EA200600078A priority patent/EA012429B1/en
Priority to UAA200600637A priority patent/UA96115C2/en
Priority to CN2004800242077A priority patent/CN1839118B/en
Publication of WO2004113275A2 publication Critical patent/WO2004113275A2/en
Publication of WO2004113275A3 publication Critical patent/WO2004113275A3/en
Priority to IL172194A priority patent/IL172194A/en
Priority to NO20055894A priority patent/NO335084B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/69—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a carbon skeleton substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/02—Thiosulfates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
PCT/IB2004/002375 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases WO2004113275A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
UAA200600637A UA96115C2 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
CN2004800242077A CN1839118B (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
BRPI0411743-3A BRPI0411743A (en) 2003-06-23 2004-06-21 method and compositions for treating amyloid-related diseases
AU2004249529A AU2004249529A1 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
MXPA05014166A MXPA05014166A (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases.
CA2529257A CA2529257C (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
EP04744034A EP1644325A2 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
KR1020057024647A KR101124935B1 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
NZ544684A NZ544684A (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
JP2006516599A JP5146714B2 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
EA200600078A EA012429B1 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
IL172194A IL172194A (en) 2003-06-23 2005-11-24 Compound and pharmaceutical composition comprising it for treating or preventing an amyloid related disease or condition
NO20055894A NO335084B1 (en) 2003-06-23 2005-12-12 Compounds and Preparations and Their Use for the Treatment of Amyloid-Related Diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US48090603P 2003-06-23 2003-06-23
US60/480,906 2003-06-23
US51204703P 2003-10-17 2003-10-17
US60/512,047 2003-10-17
US10/871,514 2004-06-18
US10/871,365 2004-06-18
US10/871,514 US7414076B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,365 US7244764B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases

Publications (2)

Publication Number Publication Date
WO2004113275A2 WO2004113275A2 (en) 2004-12-29
WO2004113275A3 true WO2004113275A3 (en) 2005-10-27

Family

ID=33545555

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2004/002375 WO2004113275A2 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
PCT/IB2004/002337 WO2004113277A2 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002337 WO2004113277A2 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases

Country Status (12)

Country Link
EP (2) EP1644325A2 (en)
JP (2) JP2007516938A (en)
KR (1) KR101124935B1 (en)
AU (2) AU2004249529A1 (en)
BR (1) BRPI0411743A (en)
CA (2) CA2529257C (en)
EA (1) EA012429B1 (en)
MX (2) MXPA05013977A (en)
NO (1) NO335084B1 (en)
NZ (1) NZ544684A (en)
UA (1) UA96115C2 (en)
WO (2) WO2004113275A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101608445B1 (en) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
JP2007516938A (en) * 2003-06-23 2007-06-28 ニューロケム （インターナショナル） リミテッド Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CN101103018A (en) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 Compounds for the treatment of CNS and amyloid associated diseases
JP5145537B2 (en) * 2004-12-22 2013-02-20 ビーエイチアイ リミテッド パートナーシップ Methods and compositions for treating amyloid-related diseases
CA2624693A1 (en) * 2005-09-30 2007-06-07 Neurochem (International) Limited Pharmaceutical compositions comprising carboxyalkylsulfonic acids
CN101534826A (en) 2006-04-14 2009-09-16 普拉纳生物技术有限公司 Method of treatment of age-related macular degeneration(amd)
KR100883132B1 (en) 2006-10-24 2009-02-10 재단법인서울대학교산학협력재단 Cleavage Agents Acting Selectively on Soluble Aggregates of Amyloid-forming Peptides or Proteins
US8212132B2 (en) 2007-03-07 2012-07-03 Massachusetts Institute Of Technology Functionalization of nanoscale articles including nanotubes and fullerenes
US8536371B2 (en) * 2007-04-02 2013-09-17 University Of South Alabama Carbon dioxide scrubbing using ionic materials
EP2247558B2 (en) 2008-02-14 2024-07-03 Eli Lilly and Company Novel imaging agents for detecting neurological dysfunction
US8951473B2 (en) 2008-03-04 2015-02-10 Massachusetts Institute Of Technology Devices and methods for determination of species including chemical warfare agents
CA2733390A1 (en) 2008-08-01 2010-02-04 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
JP2012501344A (en) * 2008-08-29 2012-01-19 トレヴェンティス コーポレイション Compositions and methods for treating amyloidosis
US8735313B2 (en) 2008-12-12 2014-05-27 Massachusetts Institute Of Technology High charge density structures, including carbon-based nanostructures and applications thereof
US8456073B2 (en) 2009-05-29 2013-06-04 Massachusetts Institute Of Technology Field emission devices including nanotubes or other nanoscale articles
WO2011017800A1 (en) 2009-08-10 2011-02-17 Bellus Health (International) Limited Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid
WO2011044221A2 (en) 2009-10-06 2011-04-14 Massachusetts Institute Of Technology Method and apparatus for determining radiation
KR101173677B1 (en) * 2009-12-11 2012-08-13 한국과학기술연구원 Pharmaceutical composition for preventing or treating diseases associated with beta amyloid accumulation containing EPPS as an active ingredient
WO2012015019A1 (en) * 2010-07-28 2012-02-02 住友化学株式会社 Manufacturing method for aminoalkyl thiosulfuric acid compound
US8476510B2 (en) 2010-11-03 2013-07-02 Massachusetts Institute Of Technology Compositions comprising and methods for forming functionalized carbon-based nanostructures
CA2995093A1 (en) * 2015-08-10 2017-02-16 Alzheon, Inc. Compositions and methods for treating and preventing neurodegenerative disorders
JP6675167B2 (en) * 2015-08-28 2020-04-01 シスメックス株式会社 Method for releasing and recovering peptide, peptide releasing agent and reagent kit
US9556301B1 (en) 2015-12-02 2017-01-31 King Fahd Universoty of Petroleum and Minerals Cyclopolymer containing residues of methionine and synthesis and uses thereof
US10632084B2 (en) 2016-03-04 2020-04-28 Niigata University Aquaporin 4 function promotor and pharmaceutical composition for neurological disorders
RU2657844C1 (en) * 2017-01-09 2018-06-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Method of treatment an experimental amyloid cardiopathy in rats
US11505467B2 (en) 2017-11-06 2022-11-22 Massachusetts Institute Of Technology High functionalization density graphene
BR112020018094A2 (en) 2018-03-08 2020-12-22 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-¿INHIBITORS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN112912732A (en) * 2018-08-03 2021-06-04 香港大学 Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, RNA, and nucleoli
JP7629182B2 (en) 2020-10-02 2025-02-13 Ｏ－Ｆｏｒｃｅ合同会社 Amyloid β aggregation inhibitor, pharmaceutical composition for amyloid β aggregation disease, and use thereof
EP3992182A1 (en) 2020-10-28 2022-05-04 Cisbio Bioassays Europium(iii) complexes as ph sensors
US20240092737A1 (en) * 2021-01-11 2024-03-21 Helios Huaming Biopharma Co., Ltd. Substituted salicylamide compounds and use thereof
CN113433325A (en) * 2021-06-07 2021-09-24 西安市第一医院 Application of serum vitronectin in diagnosis and disease classification of AL amyloidosis
EP4514335A1 (en) 2022-04-28 2025-03-05 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases
WO2024119183A1 (en) 2022-12-02 2024-06-06 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085134A (en) * 1974-02-15 1978-04-18 Petrolite Corporation Amino-phosphonic-sulfonic acids
WO1996028187A1 (en) * 1995-03-15 1996-09-19 Queen's University At Kingston Method for treating amyloidosis
WO1997014306A1 (en) * 1995-10-17 1997-04-24 Dovetail Technologies, Inc. Low molecular weight cell, bone marrow and immune stimulants
WO2000064420A2 (en) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions and methods for treating amyloidosis using sulphonate derivatives
WO2000071101A2 (en) * 1999-05-24 2000-11-30 Queen's University At Kingston Methods and compounds for inhibiting amyloid deposits
WO2001003680A2 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2376911A (en) * 1941-12-24 1945-05-29 Swiss Company Of Soc Of Chemic Derivatives of sulphonated amines and process of preparing same
DE927992C (en) * 1952-07-27 1955-05-23 Hoechst Ag Process for the preparation of salts of 1,2-dimethyl-3-phenyl-4-amino-5-pyrazolone
US3453309A (en) * 1966-10-14 1969-07-01 Parke Davis & Co Phenylalkylaminoethyl thiosulfates
DE2140278A1 (en) * 1970-01-19 1972-03-09 Crompton and Knowles Corp., Worcester, Mass. (V.St.A.) Water-soluble dyes and dye intermediates
JPS60184564A (en) * 1984-03-05 1985-09-20 Mitsui Toatsu Chem Inc Dis-azo dichroic dye for liquid crystal, and liquid crystal composition and display apparatus containing said dye
DD287256A5 (en) * 1989-08-21 1991-02-21 Akademie Der Wissenschaften Der Ddr,De METHOD FOR PRODUCING CHIRAL WATER-SOLUBLE AMMONIUM ALKANSULFONSAEURES AND THEIR SALTS AND SULFOBETAINS
JP3070687B2 (en) * 1990-07-19 2000-07-31 日本臓器製薬株式会社 Heart disease treatment
JP3068841B2 (en) * 1990-08-23 2000-07-24 日本臓器製薬株式会社 Heart disease therapeutic agent containing aminoalkanesulfonic acid derivative as active ingredient
FR2665444B1 (en) * 1990-08-06 1992-11-27 Sanofi Sa AMINO-BENZOFURAN, BENZOTHIOPHENE OR INDOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM.
JPH0995444A (en) * 1995-10-02 1997-04-08 Teijin Ltd Agent for inhibiting agglomeration of amyloid protein
WO1998052563A1 (en) * 1997-05-21 1998-11-26 Shionogi & Co., Ltd. REMEDIES FOR DEMENTIA OF ALZHEIMER TYPE CONTAINING η-SULTAM DERIVATIVES
HUP0201020A3 (en) * 1999-02-26 2003-04-28 Bristol Myers Squibb Co Novel sulfonamide compounds and uses thereof
JP4440446B2 (en) * 1999-10-05 2010-03-24 花王株式会社 Topical skin preparation
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CA2388559A1 (en) * 1999-11-29 2001-06-07 Neurochem Inc. Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001085093A2 (en) * 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
JP2006525226A (en) * 2002-12-24 2006-11-09 ニューロケム （インターナショナル） リミテッド Therapeutic formulations for the treatment of β-amyloid related diseases
JP2007516938A (en) * 2003-06-23 2007-06-28 ニューロケム （インターナショナル） リミテッド Methods and compositions for treating amyloid-related diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085134A (en) * 1974-02-15 1978-04-18 Petrolite Corporation Amino-phosphonic-sulfonic acids
WO1996028187A1 (en) * 1995-03-15 1996-09-19 Queen's University At Kingston Method for treating amyloidosis
WO1997014306A1 (en) * 1995-10-17 1997-04-24 Dovetail Technologies, Inc. Low molecular weight cell, bone marrow and immune stimulants
WO2000064420A2 (en) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions and methods for treating amyloidosis using sulphonate derivatives
WO2000071101A2 (en) * 1999-05-24 2000-11-30 Queen's University At Kingston Methods and compounds for inhibiting amyloid deposits
WO2001003680A2 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
ABDERHALDEN; RIESZ, FERMENTFORSCHUNG, 12, 1930, pages 198 *
ALLEN ET AL., ANAL. CHEM., 37, 1965, pages 156 *
CAMPAGNA F. ET AL., FARMACO, vol. 49, no. 10, 1994, pages 653 - 58 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314317, Database accession no. BRN 4261672 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314318, Database accession no. BRN 7023352 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314319, Database accession no. BRN 8919306 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314320, Database accession no. BRN 6023409 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314321, Database accession no. BRN 2272192 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314322, Database accession no. BRN 3948718 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314323, Database accession no. BRN 1712477 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314324, Database accession no. BRN 2972476 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314325, Database accession no. BRN 2434022 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314326, Database accession no. BRN 5620601 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314327, Database accession no. BRN 2846394 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314328, Database accession no. BRN 3952462, 3935697 *
DATABASE BEILSTEIN BEILSTEIN INSTITUT ZUR FÖRDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002314329, Database accession no. BRN5568774 *
DORN, WALTER, Z. CHEM., 7, 1967, pages 151 *
HELFERICH B. ET AL., JUSTUS LIEBIGS ANN. CHEM., 651, 1962, pages 33 - 42 *
IENAGA, KAZUHARA ET AL., CHEM. PHARM. BULL., vol. 36, no. 1, 1988, pages 70 - 77 *
IENAGA, KAZUHARA ET AL., CHEM. PHARM. BULL., vol. 36, no. 8, 1988, pages 2796 - 2801 *
IIDA ET AL., KOGYO KAGAKU ZASSHI, 72, 1969, pages 887 *
ISKANDER MN ET AL., EUR. J. MED. CHEM. CHIM. THER., vol. 26, no. 2, 1991, pages 129 - 136 *
JUSTUS LIEBIGS ANN. CHEM., 647, 1961, pages 37 - 40 *
KILLDAY K. B. ET AL., J. NAT. PROD., vol. 64, no. 4, 2001, pages 525 - 526 *
See also references of EP1644325A2 *
TOMSON ET AL., J. APPL. CHEM. USSR, ENGL. TRANSL., vol. 57, no. 9, 1984, pages 1885 - 91 *
WOOD. J. M. ET AL., J. CHEM. SOC. PERKIN TRANS 2, 5, 2002, pages 938 - 46 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101608445B1 (en) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Also Published As

Publication number Publication date
AU2004249527A1 (en) 2004-12-29
UA96115C2 (en) 2011-10-10
EP1644325A2 (en) 2006-04-12
EP1658264A2 (en) 2006-05-24
CA2529257A1 (en) 2004-12-29
MXPA05013977A (en) 2006-03-09
EA012429B1 (en) 2009-10-30
NZ544684A (en) 2009-10-30
JP2007516939A (en) 2007-06-28
NO335084B1 (en) 2014-09-08
KR101124935B1 (en) 2012-04-12
JP5146714B2 (en) 2013-02-20
NO20055894L (en) 2006-03-21
WO2004113277A2 (en) 2004-12-29
WO2004113277A3 (en) 2005-10-13
JP2007516938A (en) 2007-06-28
MXPA05014166A (en) 2006-03-13
EA200600078A1 (en) 2006-08-25
WO2004113275A2 (en) 2004-12-29
KR20060023172A (en) 2006-03-13
CA2529256A1 (en) 2004-12-29
WO2004113277A8 (en) 2005-07-14
CA2529257C (en) 2013-04-23
AU2004249529A1 (en) 2004-12-29
BRPI0411743A (en) 2006-08-08

Similar Documents

Publication Publication Date Title
WO2004113275A3 (en) Methods and compositions for treating amyloid-related diseases
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2006085149A3 (en) Methods and compositions for treating amyloid-related diseases
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2005046603A3 (en) Pyridine compounds
WO2003080582A3 (en) Fredericamycin derivatives
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
AU2005339139A8 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EP1638938A4 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
EP1684758A4 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
WO2007069073A3 (en) Pharmaceutical formulations of amyloid inhibiting compounds
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
AU2003258176A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024207.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172194

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005/09647

Country of ref document: ZA

Ref document number: 200509647

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004249529

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2529257

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/014166

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2004249529

Country of ref document: AU

Date of ref document: 20040621

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020057024647

Country of ref document: KR

Ref document number: 12005502335

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 2004249529

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006516599

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 544684

Country of ref document: NZ

REEP Request for entry into the european phase

Ref document number: 2004744034

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004744034

Country of ref document: EP

Ref document number: 242/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200600078

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: a200600637

Country of ref document: UA

WWP Wipo information: published in national office

Ref document number: 1020057024647

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004744034

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0411743

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载